Michael Heinrich
Michael Heinrich
Professor of Medicine, Oregon Health & Science University
Verified email at ohsu.edu - Homepage
Cited by
Cited by
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri, M Von Mehren, CD Blanke, AD Van den Abbeele, ...
New England Journal of Medicine 347 (7), 472-480, 2002
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ...
The Lancet 368 (9544), 1329-1338, 2006
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich, CL Corless, A Duensing, L McGreevey, CJ Chen, N Joseph, ...
Science 299 (5607), 708-710, 2003
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor
MC Heinrich, CL Corless, GD Demetri, CD Blanke, M Von Mehren, ...
Journal of clinical oncology 21 (23), 4342-4349, 2003
Biology of gastrointestinal stromal tumors
CL Corless, JA Fletcher, MC Heinrich
Journal of Clinical Oncology 22 (18), 3813-3825, 2004
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
MC Heinrich, DJ Griffith, BJ Druker, CL Wait, KA Ott, AJ Zigler
Blood, The Journal of the American Society of Hematology 96 (3), 925-932, 2000
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare, DK Walters, EP Stoffregen, T Jia, PW Manley, J Mestan, ...
Cancer research 65 (11), 4500-4505, 2005
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the …
CD Blanke, C Rankin, GD Demetri, CW Ryan, M Von Mehren, ...
Journal of clinical oncology 26 (4), 626-632, 2008
Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors …
CD Blanke, GD Demetri, M Von Mehren, MC Heinrich, B Eisenberg, ...
Journal of clinical oncology 26 (4), 620-625, 2008
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
AM O'Farrell, TJ Abrams, HA Yuen, TJ Ngai, SG Louie, KWH Yee, ...
Blood, The Journal of the American Society of Hematology 101 (9), 3597-3605, 2003
PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
CL Corless, A Schroeder, D Griffith, A Town, L McGreevey, P Harrell, ...
Journal of clinical oncology 23 (23), 5357-5364, 2005
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors
MC Heinrich, CL Corless, CD Blanke, GD Demetri, H Joensuu, ...
Journal of clinical oncology 24 (29), 4764-4774, 2006
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies
MC Heinrich, CD Blanke, BJ Druker, CL Corless
Journal of clinical oncology 20 (6), 1692-1703, 2002
Clinical management of gastrointestinal stromal tumors: before and after STI-571
RP Dematteo, MC Heinrich, ER Wa'el M, G Demetri
Human pathology 33 (5), 466-477, 2002
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor
MC Heinrich, RG Maki, CL Corless, CR Antonescu, A Harlow, D Griffith, ...
Journal of clinical oncology 26 (33), 5352, 2008
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status
RB West, CL Corless, X Chen, BP Rubin, S Subramanian, K Montgomery, ...
The American journal of pathology 165 (1), 107-113, 2004
Gastrointestinal stromal tumour
BP Rubin, MC Heinrich, CL Corless
The Lancet 369 (9574), 1731-1741, 2007
Gastrointestinal stromal tumours: origin and molecular oncology
CL Corless, CM Barnett, MC Heinrich
Nature Reviews Cancer 11 (12), 865-878, 2011
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal …
MC Heinrich, K Owzar, CL Corless, D Hollis, EC Borden, CDM Fletcher, ...
Journal of clinical oncology 26 (33), 5360, 2008
KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications
F Medeiros, CL Corless, A Duensing, JL Hornick, AM Oliveira, ...
The American journal of surgical pathology 28 (7), 889-894, 2004
The system can't perform the operation now. Try again later.
Articles 1–20